Skip to main content
Top
Published in: Familial Cancer 1/2017

Open Access 01-01-2017 | Short Communication

Dilemmas in the management of screen-detected lesions in patients at high risk for pancreatic cancer

Authors: Isaura S. Ibrahim, Bert A. Bonsing, Rutger-Jan Swijnenburg, Lieke Welling, Roeland A. Veenendaal, Martin N. J. M. Wasser, Hans Morreau, Akin Inderson, Hans F. A. Vasen

Published in: Familial Cancer | Issue 1/2017

Login to get access

Abstract

In 3–5 % of all cases of pancreatic ductal adenocarcinoma (PDAC), hereditary factors influence etiology. While surveillance of high-risk individuals may improve the prognosis, this study describes two very different outcomes in patients with screen-detected lesions. In 2000, a surveillance program of carriers of a CDKN2A/p16-Leiden-mutation consisting of annual MRI was initiated. Patients with a suspected pancreatic lesion undergo CT-scan and Endoscopic Ultrasound, and surgery is offered when a lesion is confirmed. In 2015, two patients with a screen-detected solid lesion were identified. In both patients, lesions were visible on MRI and CT scan, while the EUS was unremarkable. Surgical resection of the head of the pancreas resulted in nearly fatal complications in the first patient. This patient was shown to have a benign lesion. In contrast, timely identification of an early cancer in the second patient was accompanied by an uneventful postoperative course. These cases underline the risks inherent to a PDAC prevention program. All patients should be fully informed about the possible outcomes before joining a surveillance program.
Literature
1.
2.
go back to reference Shi C, Hruban RH, Klein AP (2009) Familial pancreatic cancer. Arch Pathol Lab Med 133(3):365–374PubMed Shi C, Hruban RH, Klein AP (2009) Familial pancreatic cancer. Arch Pathol Lab Med 133(3):365–374PubMed
3.
go back to reference Bartsch DK, Gress TM, Langer P (2012) Familial pancreatic cancer—current knowledge. Nat Rev Gastroenterol Hepatol 9(8):445–453CrossRefPubMed Bartsch DK, Gress TM, Langer P (2012) Familial pancreatic cancer—current knowledge. Nat Rev Gastroenterol Hepatol 9(8):445–453CrossRefPubMed
4.
go back to reference Canto MI, Goggins M, Hruban RH, Petersen GM, Giardiello FM, Yeo C et al (2006) Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4(6):766–781CrossRefPubMed Canto MI, Goggins M, Hruban RH, Petersen GM, Giardiello FM, Yeo C et al (2006) Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4(6):766–781CrossRefPubMed
5.
go back to reference Harinck F, Konings IC, Kluijt I, Poley JW, van Hooft JE, van Dullemen HM, et al (2015) A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals. Gut 1–9. doi:10.1136/gutjnl2014308008 Harinck F, Konings IC, Kluijt I, Poley JW, van Hooft JE, van Dullemen HM, et al (2015) A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals. Gut 1–9. doi:10.​1136/​gutjnl2014308008​
6.
go back to reference Vasen HF, Wasser M, van Mil A, Tollenaar RA, Konstantinovski M, Gruis NA et al (2011) Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 140(3):850–856CrossRefPubMed Vasen HF, Wasser M, van Mil A, Tollenaar RA, Konstantinovski M, Gruis NA et al (2011) Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 140(3):850–856CrossRefPubMed
7.
go back to reference Hackel BJ, Kimura RH, Miao Z, Liu H, Sathirachinda A, Cheng Z et al (2013) 18F-fluorobenzoate-labeled cystine knot peptides for PET imaging of integrin alphavbeta6. J Nucl Med 54(7):1101–1105CrossRefPubMedPubMedCentral Hackel BJ, Kimura RH, Miao Z, Liu H, Sathirachinda A, Cheng Z et al (2013) 18F-fluorobenzoate-labeled cystine knot peptides for PET imaging of integrin alphavbeta6. J Nucl Med 54(7):1101–1105CrossRefPubMedPubMedCentral
8.
go back to reference Slater EP, Fendrich V, Strauch K, Rospleszcz S, Ramaswamy A, Matthai E et al (2013) LCN2 and TIMP1 as potential serum markers for the early detection of familial pancreatic cancer. Transl Oncol 6(2):99–103CrossRefPubMedPubMedCentral Slater EP, Fendrich V, Strauch K, Rospleszcz S, Ramaswamy A, Matthai E et al (2013) LCN2 and TIMP1 as potential serum markers for the early detection of familial pancreatic cancer. Transl Oncol 6(2):99–103CrossRefPubMedPubMedCentral
9.
go back to reference Slater EP, Strauch K, Rospleszcz S, Ramaswamy A, Esposito I, Kloppel G et al (2014) MicroRNA-196a and -196b as potential biomarkers for the early detection of familial pancreatic cancer. Transl Oncol 7(4):464–471CrossRefPubMedPubMedCentral Slater EP, Strauch K, Rospleszcz S, Ramaswamy A, Esposito I, Kloppel G et al (2014) MicroRNA-196a and -196b as potential biomarkers for the early detection of familial pancreatic cancer. Transl Oncol 7(4):464–471CrossRefPubMedPubMedCentral
10.
go back to reference Potjer TP, Mertens BJ, Nicolardi S, van der Burgt YE, Bonsing BA, Mesker WE et al (2016) Application of a serum protein signature for pancreatic cancer to separate cases from controls in a pancreatic surveillance cohort. Transl Oncol 9(3):242–247CrossRefPubMedPubMedCentral Potjer TP, Mertens BJ, Nicolardi S, van der Burgt YE, Bonsing BA, Mesker WE et al (2016) Application of a serum protein signature for pancreatic cancer to separate cases from controls in a pancreatic surveillance cohort. Transl Oncol 9(3):242–247CrossRefPubMedPubMedCentral
11.
go back to reference Diener MK, Seiler CM, Rossion I, Kleeff J, Glanemann M, Butturini G et al (2011) Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. Lancet 377(9776):1514–1522CrossRefPubMed Diener MK, Seiler CM, Rossion I, Kleeff J, Glanemann M, Butturini G et al (2011) Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. Lancet 377(9776):1514–1522CrossRefPubMed
12.
go back to reference Keck T, Wellner UF, Bahra M, Klein F, Sick O, Niedergethmann M et al (2016) Pancreatogastrostomy versus pancreatojejunostomy for RECOnstruction After PANCreatoduodenectomy (RECOPANC, DRKS 00000767): perioperative and long-term results of a multicenter randomized controlled trial. Ann Surg 263(3):440–449CrossRefPubMedPubMedCentral Keck T, Wellner UF, Bahra M, Klein F, Sick O, Niedergethmann M et al (2016) Pancreatogastrostomy versus pancreatojejunostomy for RECOnstruction After PANCreatoduodenectomy (RECOPANC, DRKS 00000767): perioperative and long-term results of a multicenter randomized controlled trial. Ann Surg 263(3):440–449CrossRefPubMedPubMedCentral
13.
go back to reference Pandharipande PV, Jeon A, Heberle CR, Dowling EC, Kong CY, Chung DC et al (2015) Screening for pancreatic adenocarcinoma in BRCA2 mutation carriers: results of a disease simulation model. EBioMedicine 2(12):1980–1986CrossRefPubMedPubMedCentral Pandharipande PV, Jeon A, Heberle CR, Dowling EC, Kong CY, Chung DC et al (2015) Screening for pancreatic adenocarcinoma in BRCA2 mutation carriers: results of a disease simulation model. EBioMedicine 2(12):1980–1986CrossRefPubMedPubMedCentral
14.
go back to reference Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthai E, Carrato A et al (2016) Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three european expert centers. J Clin Oncol 34(17):2010–2019CrossRefPubMed Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthai E, Carrato A et al (2016) Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three european expert centers. J Clin Oncol 34(17):2010–2019CrossRefPubMed
Metadata
Title
Dilemmas in the management of screen-detected lesions in patients at high risk for pancreatic cancer
Authors
Isaura S. Ibrahim
Bert A. Bonsing
Rutger-Jan Swijnenburg
Lieke Welling
Roeland A. Veenendaal
Martin N. J. M. Wasser
Hans Morreau
Akin Inderson
Hans F. A. Vasen
Publication date
01-01-2017
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2017
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-016-9915-3

Other articles of this Issue 1/2017

Familial Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine